title: [Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?]
abstract: Radical cystectomy with extended pelvic lymph node dissection remains the standard of care for non-metastatic muscle-invasive bladder cancer. Locoregional control is a key factor in the outcome of patients since it is related to overall survival, metastasis-free survival and specific survival. Locoregional recurrence rate is directly correlated to pathological results and the quality of lymphadenectomy. In addition, while pre- or postoperative chemotherapy improved overall survival, it showed no impact on locoregional recurrence-free survival. Several recent publications have led to the development of a nomogram that predicts the risk of locoregional recurrence, in order to identify patients for which adjuvant radiotherapy could be beneficial. International cooperative groups have then come together to provide the rational for adjuvant radiotherapy, reinforced by recent technical developments limiting toxicity, and to develop prospective studies to reduce the risk of relapse. The aim of this critical literature review is to provide an overview of the elements in favor of adjuvant radiation for patients treated for muscle-invasive bladder cancer.
authors.affiliation: Département de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France. Electronic address: p.sargos@bordeaux.unicancer.fr.
authors.forename: P
authors.initials: P
authors.lastname: Sargos
authors.affiliation: Service d'urologie, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France.
authors.forename: S
authors.initials: S
authors.lastname: Larré
authors.affiliation: Département de radiothérapie, CHU Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: O
authors.initials: O
authors.lastname: Chapet
authors.affiliation: Département de radiothérapie, groupe Oncorad Garonne, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France.
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.affiliation: Département d'oncologie médicale, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Fléchon
authors.affiliation: Département d'oncologie médicale, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Roubaud
authors.affiliation: Département de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Orré
authors.affiliation: Département de physique médicale, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Belhomme
authors.affiliation: Département de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Richaud
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015653:Cystectomy; D006801:Humans; D008197:Lymph Node Excision; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D018579:Patient Selection; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy* / Q000601:surgery
keywords: Adjuvant radiotherapy; Bladder neoplasm; Cystectomie; Cystectomy; Locoregional relapse; Radiothérapie adjuvante; Radiothérapie conformationelle avec modulation d’intensité; Rechute locorégionale